Treating moderately to severely active ulcerative colitis - NICE TA828
1.1 Ozanimod is recommended as an option for treating moderately to severely active ulcerative colitis in adults, only if:
conventional treatment cannot be tolerated or is not working well enough and infliximab is not suitable, or
biological treatment cannot be tolerated or is not working well enough, and
the company provides it according to the commercial arrangement.